Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Biodexa Pharmaceuticals

    Client Virtual Booth

    BIODEXA PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Biodexa Pharmaceuticals
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    1 Caspian Point Caspian Way Cardiff CF10 4DQ
    Telephone
    Telephone
    +44 (0)2920480180
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://biodexapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biodexa/?originalSubdomain=uk
    Twitter
    Twitter
    https://twitter.com/biodexa_pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Biodexa Announces Phase 2 Results of eRapa™ in Familial Adenomatous Polyposis
    Biodexa Announces Phase 2 Results of eRapa™ in Familial Adenomatous Polyposis

    https://www.globenewswire.com/news-release/2024/06/24/2902967/0/en/Biodexa-Announces-Positive-Phase-2-Clinical-Trial-Results-of-eRapa-at-12-months-in-Familial-Adenomatous-Polyposis-FAP.html

    GLOBENEWSWIRE
    24 Jun 2024
    Share Share
    Results of Annual General Meeting
    Results of Annual General Meeting

    https://www.globenewswire.com/news-release/2024/06/13/2898369/0/en/Results-of-Annual-General-Meeting.html

    GLOBENEWSWIRE
    13 Jun 2024
    Share Share
    eRapa FAP Phase 2 Data To Be Presented At InSIGHT 2024 In Barcelona
    eRapa FAP Phase 2 Data To Be Presented At InSIGHT 2024 In Barcelona

    https://www.globenewswire.com/news-release/2024/06/10/2895984/0/en/Twelve-month-Phase-2-Clinical-Trial-Results-of-eRapa-in-Familial-Adenomatous-Polyposis-FAP-to-be-Presented-at-Prestigious-Biennial-InSIGHT-2024-Meeting-in-Barcelona.html

    GLOBENEWSWIRE
    10 Jun 2024
    Share Share
    Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
    Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

    https://www.globenewswire.com/news-release/2024/05/22/2886500/0/en/Biodexa-Announces-7-Million-of-Gross-Proceeds-from-Warrant-Exercises.html

    GLOBENEWSWIRE
    22 May 2024
    Share Share
    Biodexa's eRapa Shows Positive Phase 2 FAP Data At DDW 2024
    Biodexa's eRapa Shows Positive Phase 2 FAP Data At DDW 2024

    https://www.globenewswire.com/news-release/2024/05/21/2885569/0/en/Positive-Statistically-Significant-Phase-2-Clinical-Trial-Results-of-Biodexa-s-Newly-licensed-eRapa-in-Familial-Adenomatous-Polyposis-FAP-Scheduled-for-Presentation-at-the-2024-Dig.html

    GLOBENEWSWIRE
    21 May 2024
    Share Share
    Posting of Annual Report & Notice of AGM - Total Voting Rights
    Posting of Annual Report & Notice of AGM - Total Voting Rights

    https://www.globenewswire.com/news-release/2024/05/15/2882140/0/en/Posting-of-Annual-Report-Notice-of-AGM-Total-Voting-Rights.html

    GLOBENEWSWIRE
    15 May 2024
    Share Share
    Biodexa Licenses Phase 3 Asset eRapa„ for FAP Treatment
    Biodexa Licenses Phase 3 Asset eRapa„ for FAP Treatment

    https://www.globenewswire.com/news-release/2024/04/26/2870466/0/en/Biodexa-Enters-Into-Exclusive-License-to-eRapa-a-Phase-3-Ready-Asset-for-the-Treatment-of-Familial-Adenomatous-Polyposis-FAP.html

    GLOBENEWSWIRE
    26 Apr 2024
    Share Share
    Preliminary Results for the Year Ended 31 December 2023
    Preliminary Results for the Year Ended 31 December 2023

    https://www.globenewswire.com/news-release/2024/04/19/2866120/0/en/Preliminary-Results-for-the-Year-Ended-31-December-2023.html

    GLOBENEWSWIRE
    19 Apr 2024
    Share Share
    Biodexa Announces Positive Ph I Trial Results for Diffuse Midline Glioma
    Biodexa Announces Positive Ph I Trial Results for Diffuse Midline Glioma

    https://www.globenewswire.com//news-release/2024/02/23/2834442/0/en/Biodexa-Announces-Positive-Top-Line-Phase-I-Clinical-Trial-Results-for-Diffuse-Midline-Glioma-and-Provides-R-D-Update.html

    GLOBENEWSWIRE
    23 Feb 2024
    Share Share
    Biodexa Reports Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma
    Biodexa Reports Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma

    https://www.globenewswire.com//news-release/2024/02/08/2826009/0/en/Biodexa-Reports-12-Month-Survival-in-MAGIC-G1-Study-of-MTX110-in-Recurrent-Glioblastoma-Patients.html

    GLOBENEWSWIRE
    08 Feb 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search